Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Eli Lilly and other ETFs, options, and stocks.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
43,000
Employees43,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
43,000
Employees43,000

LLY Key Statistics

Market cap
709.97B
Market cap709.97B
Price-Earnings ratio
129.41
Price-Earnings ratio129.41
Dividend yield
0.62%
Dividend yield0.62%
Average volume
2.24M
Average volume2.24M
High today
$753.82
High today$753.82
Low today
$751.95
Low today$751.95
Open price
$751.90
Open price$751.90
Volume
3.14K
Volume3.14K
52 Week high
$800.78
52 Week high$800.78
52 Week low
$367.35
52 Week low$367.35

LLY News

Reuters 57m
UPDATE 1-Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients

(Adds details and background in paragraphs 2-5) April 17 (Reuters) - Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with...

UPDATE 1-Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients
New York Times 1h
Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports - The New York Times

The pharmaceutical manufacturer Eli Lilly announced on Wednesday that its obesity drug tirzepatide, or Zepbound, provided considerable relief to overweight or o...

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports - The New York Times
CNBC 1h
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials - CNBC

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popu...

Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials - CNBC

Analyst ratings

72%

of 29 ratings
Buy
72.4%
Hold
20.7%
Sell
6.9%

More LLY News

CNN 1h
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says - CNN

CNN — Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from...

Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says - CNN
NBC News 1h
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company says - NBC News

Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructiv...

Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company says - NBC News
Bloomberg 1h
Lilly's Weight-Loss Drug Helped Sleep Apnea Symptoms in Studies - Bloomberg

Eli Lilly & Co.’s weight-loss drug Zepbound improved breathing problems in highly anticipated studies that may convince more insurers to cover the $1,000-a-mont...

Lilly's Weight-Loss Drug Helped Sleep Apnea Symptoms in Studies - Bloomberg
Seeking Alpha 14h
Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration - Seeking Alpha

Precision BioSciences (NASDAQ:DTIL) said Eli Lilly (LLY) subsidiary Prevail Therapeutics has decided to conclude their gene therapy collaboration. As a result,...

Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration - Seeking Alpha
Yahoo Finance 21h
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement - Yahoo Finance

INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly w...

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement - Yahoo Finance
Seeking Alpha 2d
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk - Seeking Alpha

Martin Barraud We're going to engage in some buyout speculation, which is one of the main drivers for the biotech sector. When M&A volume is high, the sector t...

Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk - Seeking Alpha
Bloomberg 5d
Eli Lilly, Novo Risk Missing High Expectations, Goldman Says - Bloomberg

The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs G...

Eli Lilly, Novo Risk Missing High Expectations, Goldman Says - Bloomberg
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.